Send me a link:

*Text messaging rates may apply.

 Dow Down1.88% Nasdaq Down2.09%

More On 009420.KS



News & Info


Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates


  • Major Holders
  • Insider Transactions
  • Insider Roster


HanAll Biopharma Co., Ltd. (009420.KS)

3,910.00 Down 5.00(0.13%) 10:52PM EDT
ProfileGet Profile for:
HanAll Biopharma Co., Ltd.
I-Space Building, 11-10
6th Floor
Seoul, 138-922
South Korea - Map
Phone: 82 2 2204 1753
Fax: 82 2 414 1951

Index Membership:N/A
Full Time Employees:N/A

Business Summary 

HanAll BioPharma Co., Ltd., a biopharmaceutical company, engages in the research and development of biopharmaceutical products for the treatment of oncology, fibrotic, infectious, ophthalmology, immunology, endocrinology, and cardiovascular diseases in South Korea and internationally. Its products under development include HL040-Atorvastatin and Losartan for the treatment of cardiovascular disease, such as hypertension and hyperlipidemia; Hanferon, an interferon alpha for hepatitis C patients; HL009-Adenosyl-B12 liposomal gel for atopic dermatitis; and Oral Vitatropin (Resist-hGH) in the area of endocrinology. The company is also developing HL156Can for various cancers and metastatic cancers; HL152B, a metformin butyrate for a range of cancers; HL156Fib (NCE) for peritoneal fibrosis and other fibrotic diseases; and HL036, a topical TNF-alpha inhibitor for dry eyes, refractory uveitis, and AMD. In addition, its discovery stage products comprise HL161, an Anti-FcRn mAb for pemphigus vulgaris and other autoimmune diseases. HanAll BioPharma Co., Ltd. was founded in 1973 and is headquartered in Seoul, South Korea.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on HanAll Biopharma Co., Ltd.

Key Executives 
Han-Soo Lee , 50
Managing Director and Exec. Director of Fin.
Soon-Im Lee , 44
Director of Devel. and Director
Mr. Sung-Jin Kim , 53
Managing Director and Exec. Director of HR
Mr. Seung-Kook Park Ph.D., M.B.A., 51
Head of Bio R&D
Chang-Hee Min Ph.D., 53
Head of Central R&D
Amounts are as of Dec 31, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in KRW.